RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) show strong favorable overall survival trend versus osimertinib in EGFR-mutated advanced lung cancer
Long-term data from the MARIPOSA study show improved outcomes with RYBREVANT plus LAZCLUZE™ compared to osimertinib in first-line treatment for NSCLC.